- The report does not contain any information about quantitative models or factors.

Group 1 - The pharmaceutical sector is experiencing renewed activity, with significant gains in the innovative drug index and traditional Chinese medicine index [1] - Several pharmaceutical stocks, including Chengda Pharmaceutical and Duori Pharmaceutical, reached their daily limit, indicating strong market performance [1] - The Medical Insurance Bureau of Hubei Province announced the first pricing for brain-computer interface medical services in the country, marking a significant step for this cutting-edge technology [1] Group 2 - Multiple pharmaceutical companies reported substantial increases in net profits for 2024, with Heng Rui Pharmaceutical achieving a net profit of 6.337 billion yuan, a year-on-year increase of 47.28% [1] - China Galaxy noted that the pharmaceutical sector has undergone a long adjustment period, resulting in low overall valuations and insufficient public fund holdings [1] - The industry is expected to benefit from favorable policies in 2025, highlighting the mid-to-long-term investment value in the sector [1] Group 3 - Tianfeng Securities indicated that the pharmaceutical industry is gradually returning to a normal development track amid a backdrop of ongoing anti-corruption efforts [2] - The aging population and upgraded demand quality are creating long-term investment opportunities in the sector [2] - Focus should be on innovative fields, particularly products with global sales potential and a favorable competitive landscape [2]